Lataa...
Epigenetic CRISPR screens identify Npm1 as a therapeutic vulnerability in non-small cell lung cancer
Despite advancements in treatment options, the overall cure and survival rates for non-small cell lung cancers (NSCLC) remain low. While small-molecule inhibitors of epigenetic regulators have recently emerged as promising cancer therapeutics, their application in patients with NSCLC is limited. To...
Tallennettuna:
| Julkaisussa: | Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2020
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7493834/ https://ncbi.nlm.nih.gov/pubmed/32646968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-19-3782 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|